Skip to main content
. Author manuscript; available in PMC: 2024 Oct 10.
Published in final edited form as: Circulation. 2023 Sep 8;148(15):1165–1178. doi: 10.1161/CIRCULATIONAHA.123.064170

Figure 2. HFpEF patients with CH exhibit worse diastolic dysfunction and possess elevated levels of heart failure biomarkers at baseline.

Figure 2.

A. Echocardiographic analysis of E/e’ in HFpEF patients with and without CH. Statistical significance was determined by Mann-Whitney U test (n= 35 HFpEF CH− patients and 27 HFpEF CH+ patients). B. Echocardiographic analysis of E/A in HFpEF patients with and without CH. Statistical significance was determined by Mann-Whitney U test (n= 27 HFpEF CH− patients and 22 HFpEF CH+ patients). C. Echocardiographic analysis of deceleration time in HFpEF patients with and without CH. Statistical significance was determined by Welch’s t test (n= 31 HFpEF CH− patients and 22 HFpEF CH+ patients). D. Plasma brain natriuretic peptide (BNP) levels for HFpEF patients with and without CH. Statistical significance was determined by Mann-Whitney U test (n= 45 HFpEF CH− patients and 36 HFpEF CH+ patients). E. Plasma N-terminal pro b-type natriuretic peptide (NT-proBNP) levels for HFpEF patients with and without CH. Statistical significance was determined by Mann-Whitney U test (n= 45 HFpEF CH− patients and 36 HFpEF CH+ patients).